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Background: Centralization of specialist surgical services can improve patient outcomes. The aim of this
cohort study was to compare liver resection rates and survival in patients with primary colorectal cancer
and synchronous metastases limited to the liver diagnosed at hepatobiliary surgical units (hubs) with
those diagnosed at hospital Trusts without hepatobiliary services (spokes).
Methods: The study included patients from the National Bowel Cancer Audit diagnosed with primary
colorectal cancer between 1 April 2010 and 31 March 2014 who underwent colorectal cancer resection in
the English National Health Service. Patients were linked to Hospital Episode Statistics data to identify
those with liver metastases and those who underwent liver resection. Multivariable random-effects
logistic regression was used to estimate the odds ratio of liver resection by presence of specialist
hepatobiliary services on site. Survival curves were estimated using the Kaplan–Meier method.
Results: Of 4547 patients, 1956 (43⋅0 per cent) underwent liver resection. The 1081 patients diagnosed
at hubs were more likely to undergo liver resection (adjusted odds ratio 1⋅52, 95 per cent c.i. 1⋅20 to
1⋅91). Patients diagnosed at hubs had better median survival (30⋅6months compared with 25⋅3months
for spokes; adjusted hazard ratio 0⋅83, 0⋅75 to 0⋅91). There was no difference in survival between hubs
and spokes when the analysis was restricted to patients who had liver resection (P=0⋅620) or those who
did not undergo liver resection (P=0⋅749).
Conclusion: Patients with colorectal cancer and synchronous metastases limited to the liver who are
diagnosed at hospital Trusts with a hepatobiliary team on site are more likely to undergo liver resection
and have better survival.
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Introduction
Evidence has emerged over the past decade that
centralization of specialist surgical services, to create
higher-volume units, improves patient outcomes1,2. This
has had a significant effect on both organizational infra-
structure and clinical practice within the National Health
Service (NHS)3,4. In recently published plans to improve
cancer services, the NHS in England has recommended an
evaluation of whether cancer surgery would benefit from
further centralization5.
Colorectal cancer is the third most common cancer
worldwide, with over 40 000 new cases diagnosed each
year in the UK6. Synchronous liver metastases are present
in up to 20 per cent of newly diagnosed patients with
colorectal cancer7,8. Median survival with chemotherapy
alone is 6–22months9. Liver resection in suitable patients
is the only curative treatment modality and 5-year survival
rates varying from 44 to 74 per cent have been reported
following resection10–12. Wide variation in regional liver
resection rates have been demonstrated across England11.
The English Department of Health13 published guide-
lines in 2001 recommending that hepatobiliary surgery ser-
vices should be delivered by units with sufficiently large
catchment populations. As a result, hepatobiliary services
have been centralized in a hub-and-spoke arrangement,
and they are now present on site in 27 (19⋅0 per cent) of the
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142 NHS hospital Trusts that diagnose and treat patients
with colorectal cancer14.
The UK National Institute for Health and Care Excel-
lence (NICE)15 has recommended that if a colorectal can-
cer multidisciplinary team (MDT) considers both primary
and metastatic tumours potentially resectable, the patient
should be referred to a specialist hepatobiliary surgery
team. If referral pathways are working effectively, patients
diagnosed with colorectal cancer and liver metastases at
hospital Trusts with a specialist hepatobiliary team on
site should have similar liver resection rates and survival
as those diagnosed at hospital Trusts without a specialist
hepatobiliary team.
The aim of this cohort study was to compare the liver
resection rate and survival outcomes in patients diagnosed
with primary colorectal cancer and synchronousmetastases
limited to the liver at a centralized hepatobiliary centre
(hub) with those at hospital Trusts without hepatobiliary
services (spokes).
Methods
Data from the National Bowel Cancer Audit (NBOCA)14
of patients diagnosed with primary colorectal cancer
between 1 April 2010 and 31 March 2014 who underwent
a major colorectal cancer resection (right hemicolectomy,
extended right hemicolectomy, transverse colectomy, left
hemicolectomy, sigmoid colectomy, anterior resection,
abdominoperineal excision of rectum (including exenter-
ation of pelvis), Hartmann’s procedure, total colectomy
and ileorectal anastomosis, total excision of colon and
rectum, total excision of colon and rectum plus anasto-
mosis of ileum to anus plus pouch creation) in English
NHS hospitals were linked to Hospital Episode Statistics
(HES), an administrative database of all admissions to
NHS hospitals16. The NBOCA database contains data on
patients diagnosed with colorectal cancer in England. A
patient is registered in theNBOCA database at the hospital
of colorectal cancer diagnosis. Data entry is prospective
and mandatory.
Data regarding surgical urgency (elective/scheduled or
urgent/emergency), ASA fitness grade8, pathological stag-
ing and cancer site were obtained from NBOCA database.
Admission type (elective or emergency) and co-morbidity
information were obtained from the linked HES records.
The date of death was available for patients who died before
1 April 2015 and was obtained from linked data from the
Office for National Statistics (ONS)17.
Patient socioeconomic status was derived from the Index
of Multiple Deprivation (IMD)18. The IMD ranks 32 482
geographical areas of England, each of which covers a
mean population of around 1500 people or 400 households,
according to their level of deprivation measured across
seven domains. Patients are grouped into five socioeco-
nomic categories based on quintiles of the national ranking
of these areas. The Royal College of Surgeons Charlson
co-morbidity score19 was used to identify co-morbid con-
ditions in the HES records in the preceding year.
The site of metastases was identified from HES data
using diagnostic information coded according to ICD-10
(C780–C784, C786–C787, C790–C797)20. Patients were
considered to have metastatic disease at diagnosis if a HES
code was recorded up to 1 year before and 30 days after
diagnosis of colorectal cancer. A year before colorectal
cancer diagnosis was chosen to include patients who are
found to have metastases before determining the site of the
primary colorectal cancer.
Procedure information is captured in HES according to
OPCS-421. All HES records including admissions up to
31 March 2015 were searched for codes indicating a liver
resection: right hemihepatectomy (J021), left hemihepat-
ectomy (J022), resection of segment of liver (J023), wedge
excision of liver (J024), extended right hemihepatectomy
(J026), extended left hemihepatectomy (J027), partial exci-
sion of liver (J028/9), excision of lesion of liver (J031) and
extirpation of lesion of liver (J038/9).
Data regarding the presence of a specialist hepatobil-
iary team were collected in November 2015 by a national
NBOCA-led survey14. This was undertaken using an elec-
tronic questionnaire about the organization and struc-
ture of colorectal cancer services. All 142 English hospital
Trusts treating more than ten patients with colorectal can-
cer per year responded. For hospital Trusts not offering
hepatobiliary services, the Trust to which the majority of
patients were referred was ascertained. This allowed the
hospital Trusts with and without a specialist hepatobiliary
team on site to be mapped in a hub-and-spoke model. The
mapping arrangement was validated using NBOCA and
HES records linked at patient level.
Statistical analysis
The statistical significance of differences in patient char-
acteristics in hub and spoke hospital Trusts were assessed
using the χ2 test. Multivariable random-effects logistic
regression was used to estimate the odds ratio of liver
resection by presence of specialist hepatobiliary services
on site, adjusted for the following risk factors: sex, can-
cer site, IMD quintile, age group, admission type, sur-
gical urgency, Charlson co-morbidity score, T category,
N category and ASA fitness grade. A random intercept
was modelled for each hospital Trust to reflect the pos-
sible clustering of results within Trusts22. Missing values
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Patients in England aged ≥ 18 years with first
diagnosis of bowel cancer (ICD-10
C18, C19, C20) between 1 April 2010
and 31 March 2014 linked to HES
n = 137 262
Liver metastases at diagnosis
n = 17 829
Metastases in liver only
n = 11 130
Underwent bowel resection
n = 4547
No liver resection
n = 2591
Liver resection
n = 1956
No liver metastases at diagnosis
n = 119 433
Other sites of metastatic disease
n = 6699
Did not undergo resection of bowel cancer
n = 6583
Fig. 1 Flow chart showing inclusion of patients in study
for the risk factors were imputed with multiple imputation
using chained equations, creating ten data sets and using
Rubin’s rules to combine the estimated odd ratios across the
data sets23.
Survival was compared between patients with livermetas-
tases diagnosed at hospital Trusts with versus those with-
out a specialist hepatobiliary team. To avoid the need
to censor patients, survival analyses were restricted to
patients diagnosed before 1 April 2013 (with a minimum
follow-up of 2 years from the last date of death available
from ONS data). Survival curves were estimated using
the Kaplan–Meier method and differences tested with the
log rank test. Comparisons were made adjusting for other
risk factors using a multivariable Cox proportional haz-
ards model with a shared frailty factor, again to reflect the
possible clustering of results within hospitals22. STATA®
version 14.1 (StataCorp, College Station, Texas, USA) was
used for all analyses.
Results
Liver metastases were identified in HES data because
the NBOCA records only the presence, but not the site,
of metastatic disease. Of all patients undergoing major
surgery for colorectal cancer identified in the NBOCA
database to have metastatic disease at diagnosis, 41⋅1 per
cent (4098 of 9966) had a metastasis code recorded in
HES data. Despite the under-reporting of liver metas-
tases in HES, odds ratios still represent a valid measure
of the impact of the presence of a specialist hepatobiliary
team on the liver resection rate, in the same way that
an odds ratio provides a valid measure of relative risk in
case–control studies24. This approach was valid as long as
patients recorded in HES data as having liver metastases
were representative of all patients with liver metastases.
This was evaluated by twomethods: first, by comparing the
completeness of recording of metastases in HES between
hub and spoke hospital Trusts, and, second, by comparing
the characteristics of patients with metastases, irrespective
of their site, identified in the NBOCA database and corre-
sponding patients in the HES database.
Of the 9966 patients who underwent resection of the
primary colorectal cancer and had a record of metastatic
disease in the NBOCA data set, 41⋅1 per cent of those
from spoke hospital Trusts (3141 of 7644) and 41⋅2 per
cent of those from hub hospital Trusts (957 of 2322)
had a metastasis code recorded in HES. Therefore, the
recording of metastases appeared to be consistent between
both types of hospital.
Slightly more patients who had an emergency admis-
sion, urgent surgery and T4 disease were identified in the
HES database with metastatic disease than in the NBOCA,
but patient characteristics were otherwise similar (Table S1,
supporting information).
Patients
The NBOCA contained linked HES records of 137 262
patients aged 18 years or more with a primary colorectal
cancer diagnosed between 1April 2010 and 31March 2014.
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Table 1 Demographic, clinical and tumour characteristics of
patients with liver metastases undergoing colorectal cancer
resection according to whether a specialist hepatobiliary surgery
team was available on site
Spoke
hospitals
(n=3466)
Hub
hospitals
(n=1081) P*
Age (years) 0⋅150
0–64 1319 (38⋅1) 449 (41⋅5)
65–74 1161 (33⋅5) 376 (34⋅8)
75–84 813 (23⋅5) 217 (20⋅1)
≥85 173 (5⋅0) 39 (3⋅6)
Sex ratio (M : F) 2059 : 1407 633 : 448 0⋅636
Index of Multiple Deprivation <0⋅001
1 (least deprived) 450 (13⋅1) 224 (20⋅7)
2 657 (19⋅1) 225 (20⋅8)
3 729 (21⋅2) 219 (20⋅3)
4 792 (23⋅1) 210 (19⋅4)
5 (most deprived) 806 (23⋅5) 202 (18⋅7)
Missing 32 1
Admission 0⋅474
Elective 2227 (66⋅0) 702 (67⋅2)
Emergency 1145 (34⋅0) 342 (32⋅8)
Missing 94 37
Urgency of colorectal cancer resection 0⋅152
Elective/scheduled 2256 (66⋅0) 721 (68⋅4)
Urgent/emergency 1161 (34⋅0) 333 (31⋅6)
Missing 49 27
Charlson co-morbidity score 0⋅336
0 2400 (70⋅6) 760 (72⋅0)
1 776 (22⋅8) 220 (20⋅8)
≥2 222 (6⋅5) 76 (7⋅2)
Missing 68 25
ASA fitness grade 0⋅026
I 404 (13⋅3) 100 (10⋅1)
II 1603 (52⋅6) 524 (53⋅0)
III 871 (28⋅6) 316 (32⋅0)
IV or V 168 (5⋅5) 49 (5⋅0)
Missing 420 92
Cancer site 0⋅212
Ascending colon 388 (11⋅2) 110 (10⋅2)
Caecum 665 (19⋅2) 191 (17⋅7)
Rectosigmoid 273 (7⋅9) 75 (6⋅9)
Descending colon 126 (3⋅6) 37 (3⋅4)
Hepatic flexure 156 (4⋅5) 52 (4⋅8)
Rectum 551 (15⋅9) 194 (17⋅9)
Sigmoid colon 938 (27⋅1) 326 (30⋅2)
Splenic flexure 112 (3⋅2) 26 (2⋅4)
Transverse colon 257 (7⋅4) 70 (6⋅5)
T category at diagnosis 0⋅727
T0 22 (0⋅7) 7 (0⋅7)
T1 32 (1⋅0) 6 (0⋅6)
T2 156 (4⋅7) 50 (4⋅8)
T3 1577 (47⋅4) 507 (48⋅9)
T4 1540 (46⋅3) 466 (45⋅0)
Missing 139 45
N category at diagnosis 0⋅889
N0 819 (24⋅6) 249 (24⋅1)
N1 1136 (34⋅1) 361 (34⋅9)
N2 1374 (41⋅3) 425 (41⋅1)
Missing 137 46
Values in parentheses are percentages. *χ2 test.
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Fig. 2 Kaplan–Meier curves showing survival after colorectal
cancer diagnosis in patients with synchronous liver metastases,
according to diagnosis at hub (hospital Trust with on-site
hepatobiliary surgical services) or spoke (hospital Trust without
on-site hepatobiliary surgical services): a all patients, b patients
who had liver resection and c patients who did not undergo
liver resection. a P< 0⋅001, b P= 0⋅620, c P= 0⋅749 (log rank
test)
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Some 17 829 patients (13⋅0 per cent) with a code of sec-
ondarymalignant neoplasm of the liver (C787) recorded up
to 1 year before and 30 days after a diagnosis of colorectal
cancer were identified. Of these, 6699 patients with a HES
code of another site of metastasis (C780–C784, C786,
C790–C796) were excluded. A further 6583 patients who
did not have a colorectal cancer resection were excluded.
As a result, data from 4547 patients were available for anal-
ysis (Fig. 1). Liver resection was performed in 1956 of these
patients (43⋅0 per cent).
Patients diagnosed in hubs tended to have higher ASA
grade (P= 0⋅026) and lower deprivation (P< 0⋅001 for
IMD quintile) compared with those diagnosed elsewhere
(Table 1). There was no statistically significant difference in
any other patient or tumour characteristic.
Liver resection
Liver resection was performed more frequently in hubs:
545 of 1081 patients (50⋅4 per cent) who were diagnosed
in the 27 hospital Trusts with a specialist hepatobiliary
surgery team had a liver resection, compared with 1411
of 3466 (40⋅7 per cent) diagnosed elsewhere (crude odds
ratio 1⋅48, 95 per cent c.i. 1⋅29 to 1⋅70). With adjustment
for differences between the patient groups, those diagnosed
at hubs remained more likely to undergo liver resection
(adjusted odds ratio 1⋅52, 1⋅20 to 1⋅91).
A difference in liver resection rates between hubs and
spokes was seen across most regions of the country. Com-
parison of liver resection rates in hubs with the mean rates
in spokes that referred to them indicated that 21 of 27
hubs had higher liver resection rates than their respective
spoke’s mean.
Survival
Median follow-up for surviving patients was 41⋅9months.
Survival was better in hubs (median 30⋅6months compared
with 25⋅3months in spokes) (Fig. 2a), and remained so
when differences in patient and tumour characteristics
were taken into account (adjusted hazard ratio 0⋅83, 95 per
cent c.i. 0⋅75 to 0⋅91).
There was no difference in median survival between
patients diagnosed at hubs and spokes when the anal-
ysis was restricted to patients who had liver resection
(P= 0⋅620) or those who did not undergo liver resection
(P= 0⋅749) (Fig. 2b,c).
Discussion
In this national cohort of patients with colorectal cancer
and liver metastases, those who were diagnosed at hospital
Trusts with specialist hepatobiliary services on site (hubs)
were more likely to undergo liver resection and have better
survival than patients diagnosed elsewhere (spokes), after
adjusting for patient and tumour characteristics. This dis-
crepancy was present in over three-quarters of hubs and
spokes in the country. As there was no difference between
hubs and spokes in the survival of patients in this cohort
who underwent liver resection and in those who did not,
the improved overall survival for patients diagnosed at hubs
was likely to be due to the increased rate of liver resection.
Case ascertainment in the NBOCA is reported to be
94 per cent14. This high value reduced the risk of selec-
tion bias and yielded a large study cohort. The linkage
of the NBOCA data set to HES enabled the identifica-
tion of liver resection, and adjustment for differences in
patient and tumour characteristics between patients diag-
nosed in hub and spoke hospital Trusts. Linkage to ONS
mortality data allowed robust outcome ascertainment. The
data set was also linked to data from an organizational
survey regarding access to hepatobiliary services, which
was validated using information on the surgical provider
contained in HES data.
It is a limitation of this study that the presence of liver
metastases is under-recorded in HES data for patients
who did not have a liver resection. Some 13⋅0 per cent of
patients with colorectal cancer were found to have a HES
code recorded for liver metastases at the time of diagnosis,
whereas others7,8 have reported corresponding percentages
ranging from 14 to 20 per cent. Although this produces an
underestimate of the risk ratio – the ratio of the observed
percentage of patients who had a liver resection following
diagnosis in a hub (50⋅4 per cent) and the corresponding
percentage in spokes (40⋅7 per cent) – it does not affect
the odds ratio presented. This odds ratio is a valid measure
of the relative risk if patients with liver metastasis recorded
in HES are representative, and if the likelihood that a
liver metastasis is recorded in HES is the same in hub and
spoke hospitals. If liver metastases were more likely to be
recorded in the hubs than in the spokes (which is the most
probable situation if the assumption is not met), this would
underestimate the odds ratio and only further strengthen
the conclusion that liver resection rates are higher in
hospital Trusts with specialist hepatobiliary services.
A further limitation of HES is that it does not con-
tain information regarding the volume and distribution of
liver metastases. It is therefore not possible to know which
of the patients who did not undergo liver resection had
potentially operable disease. It is, however, unlikely that
the burden of liver metastases in patients would vary sub-
stantially between hospital Trusts after risk adjustment for
IMD quintile. As chemotherapy is often administered on
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an outpatient basis, reliable information regarding its use
is also not available in HES and therefore unknown for
this patient cohort. Patients undergoing radiofrequency or
microwave ablation without liver resection have not been
included as the overall rates were so low (0⋅05 per cent of
the total study cohort).
Only patients undergoing major resection of primary
colorectal cancer were included in the study cohort. The
rate of major resection of primary colorectal cancer in this
cohort was the same in hubs and spokes. A comparison
of survival of all patients with liver metastases (regardless
of primary colorectal cancer resection) between hubs and
spokes found the same increased survival in the hubs as
when the analysis was restricted to those undergoing major
resection of the primary colorectal cancer.
These results mirror those of a study25 of 95 818 patients
diagnosed with lung cancer in English NHS Trusts
between January 2008 andMarch 2012. The study demon-
strated differences in access to surgery according to hos-
pital of diagnosis; 16⋅7 per cent of patients who were first
seen in a ‘surgical centre’ underwent resectional surgery
compared with 12⋅2 per cent of those who were first seen in
a ‘non-surgical centre’. The present study of patients with
colorectal cancer and liver metastases demonstrates not
only differences in access to liver surgery between patients
diagnosed in hospital Trusts with and without a specialist
team, but also significant differences in patient survival.
A population-based study11 of all patients with colo-
rectal cancer who had a major resection in the English
NHS between 1998 and 2004 reported variation in liver
resection rates from 1⋅1 to 4⋅3 per cent across Trusts.
The results of the present study, similarly conducted
at a national level, confirm the findings of previous
single-centre or single-region studies26–29 demonstrating
the need to improve referral rates from spoke to hub hos-
pital Trusts with specialist hepatobiliary services on site.
A national study30 of 27 990 patients with colorectal cancer
treated in Sweden between 2007 and 2011 also demon-
strated higher liver resection rates in patients treated at
hub hospitals with on-site hepatobiliary services. However,
they did not find improved patient survival in hub hospitals
compared with those diagnosed at spoke hospitals.
In the present study, the patients diagnosed in spoke
hospitals were more socially deprived than those diagnosed
in hub hospitals. This may reflect the demography of the
areas served by the spoke hospitals, or may indicate that
less deprived patients are more likely to be referred to
a specialist hub unit. Comparisons of the liver resection
rates and survival across spokes and hubs were risk-adjusted
for deprivation and other factors, so this difference in
deprivation did not bias the results.
The present study, restricted to patients with colorec-
tal cancer and synchronous liver metastasis at diagnosis,
demonstrates that variation in the rate of liver resection
in England is still present. Furthermore, it indicates that
hepatobiliary service centralization, with the existence of a
hub-and-spoke arrangement, may be part of the explana-
tion. Any further centralization of cancer services should
take into consideration the impact on equity of access to
services. These findings suggest that access to specialist
hepatobiliary services is inadequate for patients diagnosed
in spoke hospital Trusts.
A possible explanation for this disparity may relate
to the complexity of managing patients with colorec-
tal cancer and synchronous liver metastases. Colorectal
multidisciplinary teams at hospital Trusts with no on-site
hepatobiliary services may have less awareness of the
availability of novel chemotherapy agents and sophisti-
cated interventional radiological techniques, which have
resulted in a widening of the definition of resectable
liver metastases31. The routine referral of all patients
diagnosed with colorectal cancer and liver metastases
for discussion at a hepatobiliary MDT meeting would
be an effective strategy for improving equality of access.
However, as many patients with metastatic colorectal
cancer would not benefit from resection but rather pal-
liative treatment, this strategy would also prove resource
intensive. The present study highlights the need for
standardization of the assessment and onward referral of
patients with metastatic colorectal cancer by colorectal
MDTs. Clearly defined and nationally agreed referral
protocols, increased attendance of hepatobiliary surgeons
at spoke colorectal cancer MDT meetings, education
programmes from hepatobiliary MDTs to colorectal can-
cer surgeons, and the use of video-conferencing between
hepatobiliary and colorectal cancer MDTs may aid this4.
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Supporting information
Additional supporting information may be found in the online version of this article:
Table S1 Comparison of characteristics of patients recorded as having metastatic disease at diagnosis in the National
Bowel Cancer Audit compared with those with a metastasis code in Hospital Episode Statistics, restricted to patients
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Editor’s comments
This research implies that patients with liver metastases should be referred to a specialized centre (i.e. a hospital with
an on-site specialized MDT). This seems to be a straightforward conclusion that is likely embraced by specialized
centres. Of more interest, however, is that an explanation for this difference in resection rates and outcome after
surgery remains largely unknown. What is the contribution of non-surgical disciplines that take part in the MDT,
including radiology for interventional techniques or medical oncology for chemotherapy?
Similar results have been shown for the surgical treatment of oesophagogastric cancer in the Netherlands suggesting
that the findings this study may be applicable to other cancer types and healthcare systems.
A weakness of the study is that only presence of liver metastases was known and not the site of metastatic disease. It is
therefore not known which of the patients who did not undergo liver resection had potentially operable disease. This
is a strong plea for registering all patients with colorectal liver metastases independent of treatment, including patients
that received palliative care only.
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